Frontiers in Cardiovascular Medicine (Apr 2023)

Case report: mRNA-1273 COVID-19 vaccine-associated myopericarditis: Successful treatment and re-exposure with colchicine

  • Luca Valore,
  • Till Junker,
  • Eva Heilmann,
  • Christine S. Zuern,
  • Christine S. Zuern,
  • Matthias Streif,
  • Beatrice Drexler,
  • Christian Arranto,
  • Jörg P. Halter,
  • Jörg P. Halter,
  • Christoph T. Berger,
  • Christoph T. Berger

DOI
https://doi.org/10.3389/fcvm.2023.1135848
Journal volume & issue
Vol. 10

Abstract

Read online

IntroductionVaccine-induced myocarditis is a rare complication of messenger RNA (mRNA) COVID-19 vaccines.Case presentationWe report a case of acute myopericarditis in a recipient of allogeneic hematopoietic cells following the first dose of the mRNA-1273 vaccine and the successful administration of a second and third dose while on prophylactic treatment with colchicine to successfully complete the vaccination.ConclusionTreatment and prevention of mRNA-vaccine-induced myopericarditis represent a clinical challenge. The use of colchicine is feasible and safe to potentially reduce the risk of this rare but severe complication and allows re-exposure to an mRNA vaccine.

Keywords